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Abstract 
Background:  Mycotic aneurysm of the thoracic or thoracoabdominal aorta and infection of thoracic or 
thoracoabdominal aortic grafts are challenging problems with high mortality.  In-situ reconstruction with 
cryopreserved allograft(CPA) avoids placement of prosthetic material in an infected field and avoids 
suppressive antibiotics or autologous tissue coverage.   
Methods:   Fifty consecutive patients with infection of a thoracic or thoracoabdominal aortic graft or 
mycotic aneurysm underwent resection and replacement with CPA from 2006 to 2016.  Intravenous 
antibiotics were continued postoperatively for 6 weeks.  Long-term suppressive antibiotics were 
uncommonly used (8 patients).   Follow up imaging occurred at 6, 18 and 42 months postoperatively.  
Initial follow up was 93% complete. 
Results:  Males comprised 64% of the cohort.  The mean age was 63±14 years.  The procedures 
performed included reoperations in 37, replacement of the aortic root, ascending aorta or transverse arch 
in 19, replacement of the descending or thoracoabdominal aorta in 27 and extensive replacement of the 
ascending, arch and descending or thoracoabdominal aorta in 4.  Intraoperative cultures revealed most 
commonly staphylococcus 24%), enterococcus (12%), candida (6%) and gram negative rods (14%).   
Operative mortality was 8%, stroke 4%, paralysis 2%, hemodialysis 6%, and respiratory failure requiring 
tracheostomy 6%.   Early reoperation for pseudoaneurysm of the CPA was necessary in 4 patients.  One, 
two and five year survival was 84%, 76% and 64%, respectively. 
Conclusions:  Radical resection and in-situ reconstruction with CPA avoids placing prosthetic material in 
an infected field and provides good early and mid-term outcomes.  However, early postoperative imaging 
is necessary given the risk of pseudoaneurysm formation. 
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An infected thoracic aortic graft is an uncommon, but challenging reoperative problem.  For patients who 
have undergone previous open repair of the thoracic aorta, the infection rate is 0.9 to 1.9% [1-4].   
Mortality for reoperative repair is 25% to 75% [2,3].  Although the increased use of endovascular 
therapies for primarily descending thoracic aortic disease has reduced morbidity for the initial repair, 
these interventions are not without infectious complication.  The infection rate of an endovascular graft is 
0.2-0.5% [5-7].   
 
Infection of the native thoracic or thoracoabdominal aorta is another uncommon surgical problem 
comprising 0.7% to 4.5% of all aortic aneurysms [8].  It has been suggested by Jaffer to treat these entities 
differently from infected aortic grafts by using operative visceral debranching and thoracic endograft 
techniques, as the reinfection risk for mycotic aneurysms is less than that of infected grafts [9].  In 
contrast to this strategy, we have approached primary aortic infections and infected aortic grafts similarly 
using radical open debridement and in-situ repair with cryopreserved allograft (CPA).  The bulk of the 
surgical literature on mycotic aortic aneurysm regards the abdominal aortic and aorto-iliac location and 
mortality is 30-40% [9,10].   
 
While prosthetic graft has a substantial risk for reinfection when placed in an infected field, CPA has 
demonstrated resistance to infection and has proven results treating prosthetic and native aortic valve 
endocarditis [8,12-16].   Operative results using CPA for native and prosthetic arterial infection still have 
significant morbidity and mortality in abdominal aortic and peripheral arterial applications, however CPA 
repair has durable and reinfection-free mid-term outcomes [17-21].  Vogt and colleagues described 
improved early and late survival using CPA with direct comparison to prosthetic graft in both thoracic 
and abdominal aortic application [22,23].  The 2016 American Heart Association Scientific Statement on 
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vascular graft infection, mycotic aneurysm and endovascular infection provides a Class IIa 
recommendation for the use of in-situ reconstruction using CPA for thoracic aortic graft infection [8]. 
 
This analysis represents the largest study of the use of CPA for in-situ reconstruction of the thoracic and 
thoracoabdominal aorta in the setting of mycotic aortic aneurysm or infection of a prosthetic aortic graft. 
 
Patients and Methods 
The Institutional Review Board of Indiana University approved the study.  A retrospective review was 
performed of fifty consecutive patients who underwent reconstruction using cryopreserved allograft for an 
infected thoracic or thoracoabdominal aortic graft or a primary infection of the thoracic or 
thoracoabdominal aorta between January 1, 2006 and December 31, 2016.   Patients with isolated aortic 
valve endocarditis (native or prosthetic), isolated infrarenal mycotic aneurysm or infected infrarenal graft 
without a proximal thoracoabdominal aneurysm who had repair with CPA were excluded from the study. 
 
The diagnosis of an infected thoracic or thoracoabdominal aortic graft was made based on the 
presentation of a constellation of 1) symptoms including fever and sepsis, 2) abnormal laboratory studies 
including elevated C-reactive protein, sedimentation rate, procalcitonin, or white blood cell count, 3) 
positive blood cultures and/or positive cultures of other infectious foci and 4) radiographic studies 
showing pseudoaneurysm, abnormal fluid or air around a surgical graft or endograft.  The diagnosis of a 
mycotic aneurysm includes 1, 2 and 3 above, and radiographic studies showing a pseudoaneurysm with or 
without stranding, periaortic fluid or air that was not thought to be an atherosclerotic penetrating aortic 
ulceration.  Radioisotope tagged white blood cell scans were not routinely used as a diagnostic study 
given its lack of specificity [8].  Positron-emission tomography with computed tomography (PET-CT) 
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was not used in this study to confirm the presence of an infected graft or mycotic pseudoaneurysm.  PET-
CT may have a high positive and negative predictive value for graft infection and provides valuable 
information in the diagnosis of mycotic aneurysm [8,24-26].  Since the conclusion of this study, we have 
been using PET-CT when other clinical features were equivocal. 
 
Patients were placed on broad spectrum or specific antibiotics according to the preoperative cultures 
obtained.  The surgical principles of radical debridement of infected and devitalized tissue, foreign 
material and prosthetic graft were followed.  Aortic reconstruction was performed using ascending/arch, 
descending aortic, aorto-iliac and femoral artery cryopreserved allograft (CryoLife, Inc., Kennesaw, GA; 
LifeNet Health, Virginia Beach, VA).   To reconstruct the main body aorta, non-valved ascending and 
arch CPAs were sutured end-to-end to reconstitute the aorta.  Occasionally, descending CPA was used for 
a smaller diameter descending or thoracoabdominal aortic reconstruction.  The brachiocephalic branches 
of the CPA arch were used to attach brachiocephalic or visceral vessels.  For thoracoabdominal aortic 
reconstruction, femoral artery and aorto-iliac CPAs were attached to the main body CPA to revascularize 
visceral arteries.  In patients with aortic repair encompassing the aortic root, ascending aorta and 
transverse arch, 1.3±0.5 ascending/arch CPAs were used.  In patients with descending or 
thoracoabdominal aortic repair, 1.9±1.0 CPAs were used.  In extensive ascending, transverse arch and 
descending or thoracoabdominal aortic reconstruction, 3.3±1.3 CPAs were required. 
 
For operations involving the descending or thoracoabdominal aorta with or without arch replacement, our 
technique has been described elsewhere using deep hypothermia and circulatory arrest [27-29].  Lumbar 
drains were not placed given the risk of epidural space infection.  Motor evoked potentials (MEPs) and 
somatosensory evoked potentials were monitored intraoperatively.  In the absence of placing lumbar 
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drains for spinal cord ischemia, if the MEPs were absent in the lower extremities, aggressive blood 
pressure elevation was initiated. 
 
Teflon-felt pledgets, which have high risk for reinfection, were avoided.  Self-made CPA tissue pledgets 
were used if the anastomoses required hemostatic sutures.  Adhesive glues or hemostatic gels were not 
used to avoid placing foreign body in the infected surgical field.   
 
Intraoperative cultures were taken to guide postoperative antimicrobial treatment.  In the event that 
preoperative and intraoperative cultures were negative, broad spectrum antibiotics were administered.  
Intravenous antimicrobials were given for 6 weeks postoperatively.  Long-term oral agents were 
administered on a case-by-case basis.  Follow up CT angiograms were performed at 6 months, one year, 
and biannually thereafter.  New pseudoaneurysm formation was interpreted as CPA suture line disruption 
and surgical reintervention was recommended.   
 
Follow up was documented in the electronic medical record of our institution.  Forty-three of 46 (93%) 
operative survivors had at least one follow up visit.  Mean follow up was 36 ± 34 months.  Median follow 
up was 25 months.   
 
Statistical Analysis 
The study is retrospective.  Continuous variables are represented as the mean with standard deviation or 
median with interquartile range (IQR).  Categorical variables are represented as the number and 
percentage of the cohort.  Mortality was identified by the electronic medical record of Indiana University 
School of Medicine, the Indiana Health Information Exchange and the Social Security death index.  
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Kaplan-Meier estimates of survivor function and corresponding 95% confidence intervals were calculated 
and plotted.  The statistical software package employed was R:A Language and Environment for 
Statistical Computing, R foundation for Statistical Computing, Vienna, Austria. 
 
 Results 
The preoperative patient characteristics are included in Table 1.  The mean age was 63 ± 14 years.  Men 
comprised 64% of the cohort.  Seventeen patents (34%) had mycotic aneurysm of the thoracic or 
thoracoabdominal aorta (Primary Mycotic group).  Thirty-three (66%) patients had an infected thoracic or 
thoracoabdominal aortic graft (Infected Graft group).  Preoperative bacteremia or fungemia was identified 
in 42% of patients.  Other presenting symptoms that were ultimately related to an infected graft or 
mycotic aneurysm included hemoptysis (12%), gastrointestinal bleed (4%).  Aortic rupture was the 
presenting event in 8%.  Pseudoaneurysm was present on CT scan in 52%. 
 
Prior open cardio-aortic operation was found in 37 patients and prior thoracic endovascular repair in 6.  
Prior operations are listed in Table 2.  Surgical procedures and extent of aortic repair performed in the 
study are found in Table 3.  The procedures performed included replacement of the aortic root, ascending 
aorta or transverse arch in 19, replacement of the descending or thoracoabdominal aorta in 27 and 
extensive replacement of the ascending, arch and descending or thoracoabdominal aorta in 4.  In Table 3, 
the procedures performed are subdivided into Infected Graft and Primary Mycotic groups.  There were 
differences in type or extent of procedures performed between the groups in regards to reoperations, 
aortic root replacement, replacement of the ascending aorta and hemiarch.  These procedures occurred 
more often in the Infected Graft group. 
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An extent II thoracoabdominal aneurysm (TAAA) repair with CPA was not performed due to the 
difficulty, complexity and extreme duration of such a procedure. The one patient had infection localized 
to the thoracic portion of the aortic graft after extent II TAAA repair and had replacement of the 
descending aorta from native aortic tissue proximally to incorporated distal descending aortic graft.  No 
attempt was made to remove all Dacron graft since the infection appeared to be localized to the 
descending aortic portion.  One patient had thoracoabdominal aortic bypass to the abdominal visceral 
arteries using CPA.  This patient had a pseudoaneurysm of the ligated infrarenal aortic stump after 
infrarenal graft excision and extraanatomic bypass.  The entire abdominal aorta was resected to place the 
aortic suture line in the thorax.  Aorto-iliac CPA was sutured end-to-end to the distal descending aorta and 
femoral artery CPA was sutured end-to-side to the aorto-iliac CPA to revascularize the visceral vessels 
individually with CPA limbs.  In all other patients, the infected grafts were completely excised and 
replaced with in-situ CPA. 
 
 Positive preoperative cultures revealed a preponderance of staphylococcus, streptococcus and 
enterococcus. Intraoperative cultures showed a preponderance of gram positive cocci, fungi, gram 
negative and anaerobic species.  Salmonella infection was uncommon (Tables 4 and 5).  Methicillin-
resistant staphylococcus aureus was present in 6 of 17 in the Primary Mycotic group and in only 1 of 33 
in the Infected Graft group.  Interestingly, preoperative cultures were the same as intraoperative cultures 
only in 18%.  Additional or different organisms by intraoperative culture were found in 6%.  Preoperative 
and intraoperative cultures were negative in 56% and 36%, respectively.   
 
Operative results are found in Table 6.  Operative mortality was 8%.  Stroke occurred in 4%, spinal cord 
ischemia in 2%.  Acute renal failure using the Society of Thoracic Surgeons definition was 20%.  Three 
patients (6%) required renal replacement therapy.  Respiratory failure occurred in 24% with 6% of 
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patients requiring tracheostomy.  In Table 6, the operative outcomes are divided into the Infected Graft 
and Primary Mycotic groups.  There were no differences in operative outcomes between the groups. 
 
Reoperations and Operative Mortality 
Eight patients required early reoperation.  Four patients developed pseudoaneurysm of the CPA repair 
within 9 months.  Three patients had reoperative repair where new CPA was used to repair the 
pseudoaneurysm.  The original CPA was preserved when possible.  Findings at reoperation revealed 
disruption of native tissue to CPA suture lines.  The fourth pseudoaneurysm patient refused reoperation 
and eventually had emergent thoracic endograft repair after pseudoaneurysm rupture.   The other patients 
who required reoperation had the following indications: 1) planned reoperation to remove descending 
followed by ascending aortic graft material, 2) persistent chylothorax, 3) postoperative hemothorax, and 
4) development of an aorto-esophageal fistula with hemorrhage.   Four patients had operative mortality 
caused by development of an aorto-esophageal fistula with hemorrhage (two patients, including the 
patient who had reoperation), a massive embolic stroke and multiorgan failure.   
 
Blood product utilization for the hospital admission is shown in Table 7.  Median packed red blood cell 
transfusion was 8 units, interquartile range 9.75.  Fresh frozen plasma usage was median of 4 units, 
interquartile range 6.  Included in Table 7 is a subgroup analysis of the Infected Graft and Primary 
Mycotic groups showing no difference in blood product utilization. 
 
Survival analysis is shown by the method of Kaplan and Meier in Figure 1. Survival analysis includes 
operative deaths.  Patients are censored after the last visit documented in the medical record.   One, two 
and five year survival was 84%, 76% and 64%, respectively for all patients.  Although not shown in the 
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figure, there was no difference in mid-term survival between the Infected Graft and Primary Mycotic 
groups.   
 
Comment 
The bulk of the surgical literature concerning mycotic aneurysm and infected aortic graft centers upon the 
abdominal aorta and iliac and femoral arteries where in-situ reconstruction or extraanatomic bypass are 
options.  Unlike the abdominal aorta and peripheral vessels, there are few instances where extraanatomic 
bypass strategies are suitable for thoracic or thoracoabdominal aortic infection or infected graft.  
Therefore, different operative strategies have been proposed including in-situ reconstruction with 
rifampin soaked Dacron, Dacron with biological tissue coverage, bovine pericardium, and cryopreserved 
allograft [3,4,11,13,17-21,30-33].   
 
Rifampin bonded Dacron with or without biological tissue coverage in abdominal aortic application can 
have reinfection rates of 22%, although others have reported reinfection rates of 0-4% on mid-term follow 
up [12,33-35].  Without exception, there is a need for lifetime suppressive antibiotics using prosthetic 
graft in an infected field [4,8].  Bovine pericardial sheets tailored to reconstruct the thoracic aorta are 
easily accessible and are easy to use, but this technique does not have extensive clinical experience or 
follow up [30]. 
 
The advantages of CPA in vascular reconstruction include its resistance to infection, extrapolation of 
known outcomes in aortic root reconstruction for endocarditis and favorable mid-term survival [8,13-
17,23,36].  The processing of the CPA involves harvesting, disinfection and cryopreservation.  Multiple 
broad spectrum antimicrobial agents are used to treat the vascular tissue which may confer resistance to 
infection.  Additionally, the immunological reaction to the cells within the extracellular matrix of the 
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CPA may also confer infection-resistance [8,14,36].  No patients in our series developed reinfection or 
deterioration of the CPA greater than 9 months after the index operation.  The 5 year survival among 
studies using CPA for aortic and arterial reconstruction is a commendable 50-60%, similar to our 5 year 
survival of 64% [17,18,23,37]. 
 
The disadvantages of CPA reconstruction include the lack of universal availability, fragility, expense, 
shape and length of the tissue, and need for early surveillance for pseudoaneurysm formation and allograft 
deterioration [18,21-23].  We have found, as have others, a risk of early failure of the CPA due to 
anastomotic pseudoaneurysm and fistula formation likely from exposure to ongoing infection 
[13,17,18,21,22,31,38].  Other mechanisms for early failure include anastomotic tension and subsequent 
breakdown, tissue friability and inadequate antimicrobial coverage [22].   
 
In our series, early or ongoing exposure to infection resulted in rupture or pseudoaneurysm formation 
within 9 months in 10% of our patients.  Upon reoperation, the defect in the repair was from deterioration 
of the CPA tissue at the suture lines.  In particular, repair of aorto-esophageal fistula with primary 
esophageal repair, autologous tissue coverage and reconstruction of the aorta with CPA in our series 
(n=2) was fraught with complication: early hemorrhage leading to death and pseudoaneurysm leading to 
reoperation.  Chiesa and colleagues also found that aorto-enteric fistulae in abdominal aortic graft 
infection are a risk factor for operative mortality using CPA [39].  As our experience with autologous 
tissue coverage in addition to CPA reconstruction has been limited to aorto-esophageal fistula repair, we 
cannot speculate upon the utility of these adjuncts to reduce the incidence of early pseudoaneurysm 
formation. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The duration of antibiotic coverage, in our institution, is typically 6 weeks after the source of an 
intravascular infection is surgically removed.  We have given oral suppressive antibiotics on a case-by-
case basis according to the virulence of the organism, fungal infection, presence of prosthetic graft or 
valve in other locations.  Eight of 50 patients had long-term oral antimicrobial therapy.  Although the 
infection-resistance of the CPA is superior to prosthetic graft, uncleared or inadequately treated infection 
may cause early graft failure [12,13,17,18,21,22,38].  It is reasonable to place all patients with infected 
aortic graft or native aorta with CPA reconstruction on 3 to 6 months of oral antibiotics after the 
intravenous course has been completed as has been suggested by the 2016 American Heart Association 
Scientific Statement [8,37].  We have changed our practice and have insisted upon at least 3 months of 
oral antimicrobial therapy after intravenous therapy has been completed. 
 
Limitations of the study include those that are inherent to an observational, single-institution, 
retrospective study.  The outcomes of the study may not be generalizable as the operations were 
performed at a tertiary care hospital by 2 surgeons (J.C. and J.F.).  Follow up for operative survivors, 
although 93%, was not complete and the etiology of late mortality was often unknown.  Late complication 
of the CPA repair may have been missed.  As a result, our survival analysis has a number of censored 
patients.  The assessment of operative candidacy was subjective, based on the surgeon’s experience and 
clinical condition of the patient.  Therefore, an unknown number of patients were not offered operative 
intervention and are not included as part of the study. 
  
 
Given the advantages and despite the disadvantages, this study demonstrates that the use of in-situ 
cryopreserved allograft is a reasonable option for the treatment of infected thoracic and thoracoabdominal 
aortic grafts and mycotic aneurysms of the thoracic and thoracoabdominal aorta.   Early pseudoaneurysm 
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formation may occur where local infection is not controlled and suture line disruption can result.  In our 
cohort after 9 months, the CPA repair has remained intact and without pseudoaneurysm formation.   
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Table 1. Patient Characteristics. 
 
n=50 % 
Age (years) 62.9±13.9 
 
Male gender 32 (64) 
Hypertension 38 (76) 
Hyperlipidemia 29 (58) 
Diabetes Mellitus 15 (30) 
Coronary artery disease 24 (48) 
Chronic kidney disease 9 (18) 
Chronic obstructive pulmonary disease 13 (26) 
Bacteremia/Fungemia 21 (42) 
Hemoptysis 6 (12) 
Gastrointestinal bleeding 2 (4) 
Rupture 4 (8) 
Pseudoaneurysm 26 (52) 
Values represented are the mean ± standard deviation or number and 
percentage of the total cohort.  Chronic kidney disease is defined as 
glomerular filtration rate  < 60 mL/min/1/73m2.  Chronic obstructive 
pulmonary disease diagnosis is based upon spirometry, clinical signs and 
symptoms.  Diabetes mellitus includes both insulin dependent and non-
insulin dependent diabetes. 
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Table 2.  Prior Operations of all patients. 
 n=50 % 
Root replacement/Bentall procedure 6 (12) 
Aortic valve replacement 4 (8) 
Ross procedure 3 (6) 
Ascending replacement 21 (42) 
Hemiarch replacement 10 (20) 
Total arch replacement 2 (4) 
Extent I TAAA 5 (10) 
Extent II TAAA 1 (2) 
Extent IV TAAA 1 (2) 
Open AAA repair 2 (4) 
TEVAR 6 (12) 
Values represented are the number and percentage of the cohort.  
TAAA=thoracoabdominal aneurysm repair, AAA=abdominal aortic 
aneurysm repair, TEVAR=thoracic endovascular aortic repair 
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Table 3.  Operations Performed with CPA. 
 All patients Infected Graft Primary Mycotic 
 n=50 % n=33 % n=17 % 
Reoperative procedure  37 (74) 33 (100) 4 (24)* 
Root replacement/Bentall 
procedure 
10 (20) 10 (30) 0 (0)* 
Aortic valve replacement 1 (2) 1 (3) 0 (0) 
Ascending replacement 22 (44) 20 (61) 2 (12)* 
Hemiarch replacement 13 (26) 13 (39) 0 (0)* 
Total arch replacement 9 (18) 7 (21) 2 (12) 
Descending replacement 17 (34) 9 (27) 8 (47) 
Extent I TAAA 8 (16) 3 (9) 5 (29) 
Extent III TAAA 1 (2) 0 (0) 1 (6) 
Extent IV TAAA 4 (8) 2 (6) 2 (12) 
Thoracoabdominal bypass 1 (2) 1 (3) 0 (0) 
 Values represented are the number and percentage of the cohort.  TAAA=thoracoabdominal aneurysm 
repair.  Significant statistical differences between the Infected Graft group and the Primary Mycotic 
group are represented by (*). 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 4.  Preoperative culture results. 
 n=50 % 
Staphylococcus 12 (24) 
Streptococcus 3 (6) 
Salmonella 2 (4) 
Enterococcus 2 (4) 
Clostridium 1 (2) 
Enterobacter 1 (2) 
Kocuria 1 (2) 
Candida 2 (4) 
Penicilium 1 (2) 
Negative 28 (56) 
Values represented are the number and percentage of the 
cohort.  Percentages do not add to 100% as some cultures 
had polymicrobial results. 
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Table 5.  Intraoperative culture results. 
 n=50 % 
Staphylococcus 12 (24) 
Enterococcus 6 (12) 
E. Coli 3 (6) 
Pseudomonas 2 (4) 
Corynebacterium 2 (4) 
Peptostreptococcus 2 (4) 
Streptococcus 2 (4) 
Salmonella 1 (2) 
Clostridium 1 (2) 
Enterobacter 1 (2) 
H. Flu 1 (2) 
Klebseilla 1 (2) 
Fusobacterium 1 (2) 
Candida 3 (6) 
Scopulaiopsis 1 (2) 
Negative 18 (36) 
Values represented are the number and percentage of the 
cohort.  Percentages do not add to 100% as some cultures had 
polymicrobial results. 
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Table 6.  Operative Results.   
 All patients Infected Graft Primary Mycotic 
 n=50 % n=33 % n=17 % 
Operative mortality 4 (8) 3 (9) 1 (6) 
Stroke 2 (4) 2 (6) 0 (0) 
Paralysis 1 (2) 1 (3) 0 (0) 
Acute renal failure 10 (20) 8 (24) 2 (12) 
       Any hemodialysis 3 (6) 2 (6) 1 (6) 
Respiratory failure 12 (24) 10 (30) 2 (12) 
       Tracheostomy 3 (6) 2 (6) 1 (6) 
Postop atrial fibrillation 3 (6) 0 (0) 3 (18) 
Reoperation 8 (16) 4 (12) 4 (24) 
Values represented are the number and percentage of the cohort.  There are no statistical differences 
between the Infected Graft group and the Primary Mycotic group. 
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Table 7.  Blood product utilization. 
 All patients      
n=50 
Infected Graft   
n=33 
Primary Mycotic 
n=17 
 Median IQR Median IQR Median IQR 
PRBC (unit) 8 9.75 8 10 6 4 
FFP (unit) 4 6 4 4 2 4 
Cryo (10 pack) 1 2 1 1 0 1 
Platelet (pheresis) 2 1 2 2 1 2 
 Values represented are median and interquartile range.  There are no statistical 
differences between the Infected Graft group and the Primary Mycotic group. 
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Figure Legend 
Figure 1. Kaplan-Meier Survival Analysis for all patients with 95% confidence intervals. Time is 
delineated in months.  The number at risk is associated with each time point. 
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